+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Psoriatic Arthritis Treatment Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, DMARDs, Biologics), By Type (Prescriptions, OTC), By Route Of Administration (Topical, Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030- Product Image
Psoriatic Arthritis Treatment Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, DMARDs, Biologics), By Type (Prescriptions, OTC), By Route Of Administration (Topical, Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030- Product Image
New

Psoriatic Arthritis Treatment Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, DMARDs, Biologics), By Type (Prescriptions, OTC), By Route Of Administration (Topical, Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 110 Pages
  • July 2025
  • Region: Global
  • Grand View Research
  • ID: 6154436
Description Jump to:

Psoriatic Arthritis Treatment Market Summary

The global psoriatic arthritis market size was estimated at USD 11.35 billion in 2024 and is projected toprojected to reach USD 19.91 billion by 2030, growing at a CAGR of 9.8% from 2025 to 2030. The new product launches, promising pipeline, a significant rise in consumer awareness, and increasing disease burden are some factors expected to fuel market growth.

Psoriatic arthritis is a chronic degenerative condition associated with psoriasis. In the absence of proper and timely treatment, the disease may lead to irreversible joint damage. Although the exact causative factors remain unknown, research suggests that nearly 40% of cases are attributable to genetic factors.

Psoriatic arthritis may be misdiagnosed as rheumatoid arthritis or gout. However, heightened consumer awareness, aided by multiple campaigns organized by private and public organizations, is likely to reduce the rates of misdiagnosis or incorrect treatment. In addition, the high cost of treatment and the adverse effects of some drugs are expected to restrain market growth.

There is a significant paradigm shift in the treatment of psoriatic arthritis, driven by the targeted action of biologics and the emergence of biosimilars. However, the consumer demand for cost-effective medicines with improved safety and efficacy profiles is likely to have a positive impact on market dynamics.

Healthcare infrastructure improvements and increased insurance coverage in emerging markets are also pivotal. Countries in Asia-Pacific and Latin America are witnessing rapid health system upgrades, enabling wider access to high-cost biologic therapies. As these markets mature, they present new opportunities for both multinational and domestic drug makers to tap into previously underserved populations.

Global Psoriatic Arthritis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the global psoriatic arthritis market report based on drug class, type, route of administration, and region:

Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

  • NSAIDs
  • DMARD
  • Biologics
  • Others

Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Prescriptions
  • OTC

Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Topical
  • Oral
  • Injectable

Regional Outlook (Revenue, USD Million, 2018 - 2026)

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Spain
  • France
  • Italy
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Type
1.2.3. Route of Administration
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Class outlook
2.2.2. Type outlook
2.2.3. Route of Administration
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Psoriatic Arthritis Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Psoriatic Arthritis Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Psoriatic Arthritis Treatment Market: Drug Class Estimates & Trend Analysis
4.1. Drug Class Segment Dashboard
4.2. Psoriatic Arthritis Treatment Market: Drug Class Movement Analysis
4.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. NSAIDs
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. DMARDs
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Biologics
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Others
4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Psoriatic Arthritis Treatment Market: Type Estimates & Trend Analysis
5.1. Type Segment Dashboard
5.2. Psoriatic Arthritis Treatment Market: Type Movement Analysis
5.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
5.4. Prescriptions
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. OTC
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Psoriatic Arthritis Treatment Market: Route of Administration Estimates & Trend Analysis
6.1. Route of Administration Segment Dashboard
6.2. Psoriatic Arthritis Treatment Market: Route of Administration Movement Analysis
6.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Topical
6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Oral
6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Injectable
6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Psoriatic Arthritis Treatment Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Continuous bioprocessing market by Region: Key Takeaways
7.4. North America
7.4.1. U.S.
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Canada
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Europe
7.5.1. UK
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. Germany
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. France
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Italy
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. Spain
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. China
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. India
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. Australia
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Argentina
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.8.2. Saudi Arabia
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.8.3. UAE
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. Key company heat map analysis, 2024
8.4. Company Profiles
8.4.1. AbbVie Inc.
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Amgen Inc.
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Johnson & Johnson Services, Inc.
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Bristol-Myers Squibb Company
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Novartis AG
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Eli Lilly and Company
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Pfizer, Inc.
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. UCB S.A.
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 Global psoriatic arthritis treatment market, by region (USD Million) 2018 - 2030
Table 3 Global psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 4 Global psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 5 Global psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 6 North America psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
Table 7 North America psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 8 North America psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 9 North America psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 10 U.S. psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 11 U.S. psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 12 U.S. psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 13 Canada psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 14 Canada psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 15 Canada psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 16 Mexico psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 17 Mexico psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 18 Mexico surgical ablation market, by route of administration (USD Million) 2018 - 2030
Table 19 Europe psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
Table 20 Europe psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 21 Europe psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 22 Europe psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 23 Germany psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 24 Germany psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 25 Germany psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 26 UK psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 27 UK psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 28 UK psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 29 France psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 30 France psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 31 France psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 32 Italy psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 33 Italy psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 34 Italy psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 35 Spain psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 36 Spain psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 37 Spain psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 38 Asia Pacific psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
Table 39 Asia Pacific psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 40 Asia Pacific psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 41 Asia Pacific psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 42 China psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 43 China psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 44 China psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 45 Japan psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 46 Japan psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 47 Japan psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 48 India psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 49 India psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 50 India psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 51 South Korea psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 52 South Korea psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 53 South Korea psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 54 Australia psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 55 Australia psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 56 Australia psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 57 Latin America psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
Table 58 Latin America psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 59 Latin America surgical ablation market, by type (USD Million) 2018 - 2030
Table 60 Latin America laparoscopic ablation market, by route of administration (USD Million) 2018 - 2030
Table 61 Latin America percutaneous ablation market, by route of administration (USD Million) 2018 - 2030
Table 62 Latin America psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 63 Brazil psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 64 Brazil psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 65 Brazil surgical ablation market, by route of administration (USD Million) 2018 - 2030
Table 66 Argentina psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 67 Argentina psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 68 Argentina surgical ablation market, by route of administration (USD Million) 2018 - 2030
Table 69 MEA psoriatic arthritis treatment market, by region (USD Million) 2018 - 2030
Table 70 MEA psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 71 MEA psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 72 MEA psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 73 South Africa psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 74 South Africa psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 75 South Africa psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 76 Saudi Arabia psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 77 Saudi Arabia psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 78 Saudi Arabia psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
Table 79 UAE psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
Table 80 UAE psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
Table 81 UAE psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Psoriatic arthritis treatment market: market outlook
Fig. 10 Psoriatic arthritis treatment competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 Psoriatic arthritis treatment market driver impact
Fig. 16 Psoriatic arthritis treatment market restraint impact
Fig. 17 Psoriatic arthritis treatment market strategic initiatives analysis
Fig. 18 Psoriatic arthritis treatment market: Drug Class movement analysis
Fig. 19 Psoriatic arthritis treatment market: Drug Class outlook and key takeaways
Fig. 20 NSAIDs market estimates and forecast, 2018 - 2030
Fig. 21 DMARDs market estimates and forecast, 2018 - 2030
Fig. 22 Biologics market estimates and forecast, 2018 - 2030
Fig. 23 Others market estimates and forecast, 2018 - 2030
Fig. 24 Psoriatic arthritis treatment Market: Type movement Analysis
Fig. 25 Psoriatic arthritis treatment market: Type outlook and key takeaways
Fig. 26 Prescriptions market estimates and forecasts, 2018 - 2030
Fig. 27 OTC market estimates and forecasts,2018 - 2030
Fig. 28 Psoriatic arthritis treatment market: Route of Administration movement analysis
Fig. 29 Psoriatic arthritis treatment market: Route of Administration outlook and key takeaways
Fig. 30 Topical market estimates and forecasts, 2018 - 2030
Fig. 31 Oral market estimates and forecasts,2018 - 2030
Fig. 32 Injectable market estimates and forecasts, 2018 - 2030
Fig. 33 Global psoriatic arthritis treatment market: Regional movement analysis
Fig. 34 Global psoriatic arthritis treatment market: Regional outlook and key takeaways
Fig. 35 North America market estimates and forecasts, 2018 - 2030
Fig. 36 U.S. market estimates and forecasts, 2018 - 2030
Fig. 37 Canada market estimates and forecasts, 2018 - 2030
Fig. 38 Mexico market estimates and forecasts, 2018 - 2030
Fig. 39 Europe market estimates and forecasts, 2018 - 2030
Fig. 40 UK market estimates and forecasts, 2018 - 2030
Fig. 41 Germany market estimates and forecasts, 2018 - 2030
Fig. 42 France market estimates and forecasts, 2018 - 2030
Fig. 43 Italy market estimates and forecasts, 2018 - 2030
Fig. 44 Spain market estimates and forecasts, 2018 - 2030
Fig. 45 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 46 China market estimates and forecasts, 2018 - 2030
Fig. 47 Japan market estimates and forecasts, 2018 - 2030
Fig. 48 India market estimates and forecasts, 2018 - 2030
Fig. 49 South Korea market estimates and forecasts, 2018 - 2030
Fig. 50 Australia market estimates and forecasts, 2018 - 2030
Fig. 51 Latin America market estimates and forecasts, 2018 - 2030
Fig. 52 Brazil market estimates and forecasts, 2018 - 2030
Fig. 53 Argentina market estimates and forecasts, 2018 - 2030
Fig. 54 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 55 South Africa market estimates and forecasts, 2018 - 2030
Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 57 UAE market estimates and forecasts, 2018 - 2030

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer, Inc.

Table Information

Report AttributeDetails
No. of Pages110
PublishedJuly 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 11.35 Billion
Forecasted Market Value ( USD ) by 2030 $ 19.91 Billion
Compound Annual Growth Rate9.8%
Regions CoveredGlobal
No. of Companies Mentioned7

Related Topics

Related Reports

Psoriatic Arthritis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 to 2032 - Product Image

Psoriatic Arthritis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 to 2032

  • Report
  • 170 Pages
  • Global
From
Psoriatic Arthritis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027 - Product Image

Psoriatic Arthritis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027

  • Report
  • 270 Pages
  • Global
From
Psoriatic Arthritis Treatment Market Report and Forecast 2023-2031 - Product Image

Psoriatic Arthritis Treatment Market Report and Forecast 2023-2031

  • Report
  • 160 Pages
  • Global
From
Psoriatic Arthritis Treatment Market Report by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type, Route of Administration, Distribution Channel, and Region 2024-2032 - Product Image

Psoriatic Arthritis Treatment Market Report by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type, Route of Administration, Distribution Channel, and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
Psoriatic Arthritis Treatment Market Report 2025 - Product Image

Psoriatic Arthritis Treatment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.